Confirmatory Trials in the Evaluation of Anticancer Medicinal Products in Man—PFS2: A Measure of Therapeutic Action-At-A-Distance
Open Access
- 1 September 2015
- Vol. 17 (9) , 716-722
Abstract
No abstract availableKeywords
This publication has 25 references indexed in Scilit:
- Comparing duration of response and duration of clinical benefit between fulvestrant treatment groups in the CONFIRM trial: application of new methodologyBreast Cancer Research and Treatment, 2013
- Alarmins: awaiting a clinical responseJournal of Clinical Investigation, 2012
- Therapeutic strategy in unresectable metastatic colorectal cancerTherapeutic Advances in Medical Oncology, 2011
- Combination Epigenetic Therapy Has Efficacy in Patients with Refractory Advanced Non–Small Cell Lung CancerCancer Discovery, 2011
- Phase 1 study of epigenetic priming with decitabine prior to standard induction chemotherapy for patients with AMLBlood, 2011
- Biomarkers and surrogate end points—the challenge of statistical validationNature Reviews Clinical Oncology, 2010
- Stop and Go: Yes or No?Journal of Clinical Oncology, 2009
- Can Chemotherapy Be Discontinued in Unresectable Metastatic Colorectal Cancer? The GERCOR OPTIMOX2 StudyJournal of Clinical Oncology, 2009
- Issues in Using Progression-Free Survival When Evaluating Oncology ProductsJournal of Clinical Oncology, 2009
- Endpoints for Assessing Drug Activity in Clinical TrialsThe Oncologist, 2008